One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology.

ABSTRACT:

Objective

The aim was to study the effect of non-mandatory transitioning from etanercept originator to etanercept biosimilar on retention rates in a setting promoting shared decision-making.

Methods

In 2016, all patients treated with etanercept originator and stable disease at the Rheumatology department in Bernhoven were offered transitioning to etanercept biosimilar by an opt-in approach. A historical cohort of patients treated with etanercept originator in 2015 was identified as the control group. Etanercept discontinuation was compared between the cohorts using Cox regression. To study the nocebo effect, reasons for discontinuation were categorized into objective reasons (e.g. laboratory abnormalities, increase in swollen joint count, allergic reaction) and subjective he

SUBMITTER: Muskens WD 

PROVIDER: S-EPMC7519774 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature